^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CTLA4 inhibitor

    Related drugs:
    2d
    Bispecific Dual-Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients. (PubMed, J Cutan Pathol)
    The eruption was refractory to treatment, despite the patient withholding lorigerlimab, leading to complete discontinuation of lorigerlimab. This report highlights the importance of histopathologic evaluation in guiding treatment decisions for lorigerlimab-associated irAEs and underscores the need for further research into its dermatologic irAEs.
    Journal • Adverse events • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    lorigerlimab (MGD019)
    2d
    Safety and Efficacy of Nivolumab Plus Ipilimumab in Microsatellite Instability-High/Mismatch Repair-Deficient Colorectal Cancer: A Systematic Review. (PubMed, Clin Oncol (R Coll Radiol))
    Nivolumab plus ipilimumab is an effective and relatively well-tolerated option for MSI-H/dMMR CRC, offering significant clinical benefit across disease stages. Ongoing trials and longer follow-up are warranted to optimise dosing, identify predictive biomarkers, and refine patient selection.
    Journal • Mismatch repair • Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    3d
    A Case of Lynch Syndrome with MLH1 Gene Mutation Identified by Comprehensive Genomic Profiling (PubMed, Gan To Kagaku Ryoho)
    Treatment with immune checkpoint inhibitors(ipilimumab plus nivolumab)was initiated. As of 4 years and 3 months post-surgery, tumor shrinkage has been sustained, with no evidence of new malignancies, recurrence, or metastasis. Given the presence of multiple colorectal cancers, a history of gynecologic malignancy, and a family history of gastrointestinal cancers, this case illustrates the importance of early consideration of hereditary tumors and highlights the clinical utility of genomic medicine.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MLH1 (MutL homolog 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    BrUOG 324: Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma (clinicaltrials.gov)
    P2, N=22, Active, not recruiting, Brown University | Trial completion date: Jul 2025 --> Jan 2026
    Trial completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    4d
    A Phase II Study of Neoadjuvant Sacituzumab Tirumotecan in Combination With Iparomlimab and Tuvonralimab in Locally Advanced Cervical Cancer (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Zheng Min
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    PD-L1 expression
    |
    Jiataile (sacituzumab tirumotecan) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    4d
    Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=46, Not yet recruiting, The Second Affiliated Hospital of Dalian Medical University
    New P2 trial
    |
    cisplatin • Yervoy (ipilimumab) • etoposide IV • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    5d
    QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Triple-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Affiliated Hospital of Nantong University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 negative
    |
    carboplatin • doxorubicin hydrochloride • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Qibeian (iparomlimab/tuvonralimab)
    5d
    A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma (clinicaltrials.gov)
    P2/3, N=600, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar) • Leukine (sargramostim)
    6d
    SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=116, Recruiting, First Affiliated Hospital of Zhejiang University | Initiation date: May 2025 --> Jan 2025 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Mismatch repair • pMMR
    |
    capecitabine • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    7d
    131I-Labeled Dual Immune Checkpoint Inhibitors for Tumor Microenvironment Improvement To Enhance Antitumor Efficacy. (PubMed, Mol Pharm)
    We used 131I-labeled cadonilimab (AK104), a PD-1/CTLA-4 tetravalent bispecific antibody, as a novel radio-immunotherapeutic agent for the treatment of non-small-cell lung cancer (NSCLC) and explored its underlying therapeutic mechanism...The combination of 131I-based radiotherapy and bispecific ICIs remodels the TME and enhances the therapeutic efficacy in NSCLC. CD8+ T cell activation and neutrophil-mediated ROS and NO release are key mechanisms contributing to enhanced tumor cell killing.
    Journal • Checkpoint inhibition
    |
    PD-1 (Programmed cell death 1)
    |
    Kaitanni (cadonilimab)
    7d
    RPx: A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3 (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Replimune Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    RP3 • Tudriqev (vusolimogene oderparepvec-wtpg) • sturlimogene erparepvec (RP2)
    7d
    Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Nov 2025 --> Apr 2026
    Trial initiation date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • Neulasta (pegfilgrastim) • Neupogen (filgrastim) • sturlimogene erparepvec (RP2)